Crossmark

The impact of DXA findings on general practitioners’ decision regarding first-line oral bisphosphonates in postmenopausal osteoporosis—data from French General Practice (the IMOGENE study)

Crossref DOI link: https://doi.org/10.1007/s11657-026-01663-3

Published Online: 2026-02-13

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Cortet, Bernard https://orcid.org/0000-0001-8912-0452
Chelbani, Leila

Garot, Térésa

Samama, Pascale

Lespessailles, Eric
Funding

Funding for this research was provided by:

Amgen

Centre Hospitalier Universitaire de Lille
License Information

Text and Data Mining valid from 2026-02-13

Version of Record valid from 2026-02-13
More Information

Article History

Received: 19 November 2025

Accepted: 25 January 2026

First Online: 13 February 2026

Declarations

:

: LC and PS are Amgen employees and stockholders. BC and EL have received consultancy fees and honoraria from AMGEN SAS for their contribution to this project.

Document is current

Any future updates will be listed below